Loading clinical trials...
Loading clinical trials...
An Open Label Study to Evaluate the Pharmacokinetics of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 mcg) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects
Conditions
Interventions
FF
VI/UMEC
Locations
1
China
GSK Investigational Site
Shanghai, China
Start Date
September 1, 2016
Primary Completion Date
November 1, 2016
Completion Date
November 1, 2016
Last Updated
January 25, 2017
NCT06831994
NCT02755974
NCT05050591
NCT05913765
NCT05592847
NCT00683722
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions